Among these still in development, Glenmark's orally active GRC17536 cleared a phase 2a study in diabetic neuropathy but has bioavailability issues that have held up a phase 3 programme.

There is decreased risk for CV events and mortality in patients with cardiac autonomic neuropathy that receive intensive glycemic treatment.

The prevalence of diabetes is increasing worldwide; however, its impact on routine daily activities is often underappreciated ...

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study. The South ...

Type 2 diabetes mellitus, the most frequent subtype of diabetes, is a disease characterized by high levels of blood glucose (hyperglycaemia). It arises from a resistance to and relative deficiency ...

While type 2 diabetes doesn’t increase a person’s hypoglycemia risk on its own, those who take insulin or medications that increase insulin production can experience low blood sugar, according ...